1. Lappano, R, Maggiolini, M, Mallet, C, Jacquot, Y(2024)Commentary: harnessing the first peptidic modulator of the estrogen receptor GPER. Front Pharmacol 15 :1413058.
  2. De Moura, A et al.(2024)Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases. Breast Cancer :.
  3. Heimfarth, L et al.(2024)The protective effects of naringenin, a citrus flavonoid, non-complexed or complexed with hydroxypropyl-β-cyclodextrin against multiorgan damage caused by neonatal endotoxemia. Int J Biol Macromol 264 (Pt 1):130500.
  4. Acramel, A et al.(2024)Advanced prescription of injectable anticancer drugs: Safety assessment in a European Comprehensive Cancer Centre using the risk matrix approach. Br J Clin Pharmacol 90 (5):1333-1343.
  5. Dudas, B, Miteva, MA(2024)Computational and artificial intelligence-based approaches for drug metabolism and transport prediction. Trends Pharmacol Sci 45 (1):39-55.
  6. Mégret-Cavalier, M et al.(2024)Starting with an Integral Membrane Protein Project for Structural Biology: Production, Purification, Detergent Quantification, and Buffer Optimization-Case Study of the Exporter CntI from Pseudomonas aeruginosa. Methods Mol Biol 2715 :415-430.
  7. Hopp, MT et al.(2024)Insights into the molecular basis and mechanism of heme-triggered TLR4 signalling: The role of heme-binding motifs in TLR4 and MD2. Immunology 171 (2):181-197.
  8. Tardy, C et al.(2024)Pazopanib pharmacokinetically guided dose optimization in three cancer patients with gastrointestinal resection. Cancer Chemother Pharmacol 93 (2):169-175.
Search PubMed